ArticleClinical cancer research : an official journal of the American Association for Cancer Research2018
Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 160 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
160citing papers in PubMed, 1 pooled it
10.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
160 citing papers in PubMed, 1 synthesis or guideline pooled it, 231 citations in OpenAlex.
- The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- S-nitrosylation topology in melanoma: established mechanisms, unresolved redox-immune links, and a testable framework.Redox biology · 2026Review
- Myeloid-derived suppressor cells in cancer: biology, regulatory networks and theranostic prospects.Signal transduction and targeted therapy · 2026Review
- Myeloid-Derived Suppressor Cells in Cancer: Metabolic Reprogramming, Immune Crosstalk, and Therapeutic Targeting.Cancers · 2026Review
- Can Complex 3D Models Effectively Replace 2D and Animal Models to Investigate the Microbe-Tumor-Immune Axis in Pancreatic Cancer Studies?Nutrients · 2026Review
- Recent Advances in Neoadjuvant Treatment of Anaplastic Thyroid Carcinoma: A Narrative Review.Current treatment options in oncology · 2026Review
- Roles of neutrophil extracellular traps in cancer immunotherapy resistance and therapeutic targeting.Biomarker research · 2026Review
- Myeloid-Derived Suppressor Cells in Sepsis: Pathophysiology, Duality, and Therapeutic Frontiers.Shock (Augusta, Ga.) · 2026Review
- Expression of Bruton's Tyrosine Kinase Reflects Immune Cells Infiltration and Cell Proliferation in Breast Cancer.World journal of oncology · 2026Article
- Metabolomic and transcriptomic analyses identify metabolic alterations and immune suppression in ovarian cancer.Scientific reports · 2026Article
- Advances in intratumoral immunotherapy from a neuro-immune-endocrine perspective for breast cancer treatment.Frontiers in oncology · 2026Review
- Extracellular Metabolites and Natural Killer Cell Antitumor Function: Mechanisms and Therapeutic Strategies.Research (Washington, D.C.) · 2026Review
- Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance.Frontiers in immunology · 2026Review
- Myeloid derived suppressor cells in neuroblastoma: mechanisms of immune evasion and therapeutic opportunities.Frontiers in immunology · 2026Review
- Gasotransmitters bridging tumor biology and immunity: from pathophysiological insights to therapeutic potential.Frontiers in immunology · 2026Review
- Monocytic Cell Variations in Postallotransplant Environment: Balancing Graft Versus Host Disease and Graft-Versus-Leukemia Effect.Journal of immunology research · 2026Review
- Harnessing the Power of CAR-NK Cells for Solid Tumors: Challenges, Innovations, and Future Frontiers in Immunotherapy.Cancer communications (London, England) · 2026Review
- Recent advances in the investigation of the regulatory network underlying reactive nitrogen species-mediated tumorigenesis: molecular mechanisms and targeted therapeutic strategies.Redox report : communications in free radical research · 2025Review
- Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer.BMC cancer · 2025Article
- CAR-NK cell therapy in multiple myeloma: from preclinical and clinical landscape to joining the force for treatment strategies optimization.Cell communication and signaling : CCS · 2025Review
100 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 1 institution in 1 country.
Andrew Stiff *Medical Scientist Training Program, Columbus, Ohio.
Prashant Trikha *Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Bethany Mundy-BosseComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Elizabeth McMichaelBiomedical Sciences Graduate Program, The Ohio State University, Columbus, Ohio.
Thomas A MaceComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Brooke BennerBiomedical Sciences Graduate Program, The Ohio State University, Columbus, Ohio.
Kari KendraDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
Amanda CampbellMedical Scientist Training Program, Columbus, Ohio.
Shalini GautamComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
David AboodComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Ian LandiComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Vincent HsuComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Megan DugganBiomedical Sciences Graduate Program, The Ohio State University, Columbus, Ohio.
Robert WesolowskiDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
Matthew OldDepartment of Otolaryngology, The Ohio State University, Columbus, Ohio.
John Harrison HowardDivision of Surgical Oncology, Department of Surgery, The Ohio State University, Columbus, Ohio.
Lianbo YuDepartment of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
Nancy StasikDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
Thomas OlenckiDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
Natarajan MuthusamyComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Susheela TridandapaniComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
John C ByrdComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
Michael CaligiuriComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
William E CarsonComprehensive Cancer Center, The Ohio State University, Columbus, Ohio. william.carson@osumc.edu.
The Ohio State University · US
Funding
Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Tasleem J Padamsee · 1985 to 2026
$132.3MTWO SIGNAL REQUIREMENT FOR NATURAL KILLER IMMUNITYP01CA095426 · NCI · OHIO STATE UNIVERSITY · PI JARJOURA, DAVID G · 2002 to 2016
$29.6MA Program of Immune-Based Treatments for CancerK24CA093670 · NCI · OHIO STATE UNIVERSITY · PI CARSON, WILLIAM E. · 2002 to 2012
$1.7MNCI NIH HHS K24 CA093670NCI NIH HHS P01 CA095426NCI NIH HHS P30 CA016058
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntibody-Dependent Cell CytotoxicityAntineoplastic AgentsCell Line, TumorCytokinesCytotoxicity, ImmunologicDisease Models, AnimalFemaleHumansKiller Cells, NaturalLymphocyte ActivationMiceMyeloid-Derived Suppressor CellsNeoplasmsNitric OxideReceptors, FcAntineoplastic AgentsCytokinesNitric OxideReceptors, Fc
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.